Most Read Articles
Tristan Manalac, 5 days ago
Left ventricular assist devices (LVADs) can reverse pulmonary hypertension secondary to left heart disease regardless of baseline pulmonary vascular resistance, according to a new study.
11 May 2019
Acute kidney injury (AKI) commonly occurs within a year after cancer diagnosis in paediatric patients and is tied to long-term deteriorations in renal function, a recent study has found.
11 May 2019
Women practicing exclusive breastfeeding for 6 months achieve greater postpartum weight loss compared with those exclusively breastfeeding for a shorter duration, according to data from the MILK* study.
Pearl Toh, 13 May 2019
The selective cap-dependent endonuclease inhibitor baloxavir marboxil (hereafter baloxavir) effectively improves influenza symptoms in adolescent patients and those at high risk for influenza complications, according to two subanalyses of the CAPSTONE studies presented at ECCMID 2019.

Savolitinib plus osimertinib combination therapy triumphs in treatment of mutated lung cancer

Dr. Joseph Delano Fule Robles
07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

The TATTON results were presented in two cohorts, each with more than 40 patients with EGFR-mutant, MET-amplified NSCLC treated with osimertinib 80 mg once daily plus savolitinib 600 mg once daily. The first cohort analyzed treatment response after progression on prior first-/second-generation EGFR tyrosine kinase inhibitor (TKI) therapy. The second cohort analyzed response to the combination therapy after progression on prior third-generation EGFR TKI therapy. [Yu H, et al, AACR 2019, abstract CT032; Sequist LV, et al, AACR 2019, abstract CT033]

Results from the first cohort (n=46; median age, 59 years; 67 percent female) showed an objective response rate (ORR) of 52 percent with the combination therapy. The median duration of response was 7.1 months. The second cohort (n=48; median age, 59 years; 56 percent male) demonstrated an ORR of 28 percent, with a median duration of response of 9.7 months.

“Data from the TATTON trial demonstrate, for the first time, the benefit of adding a MET inhibitor to an EGFR inhibitor in patients with EGFR-mutant NSCLC with MET-driven acquired resistance. The study has shown efficacy of combination targeted therapy in a patient population for whom chemotherapy is the current primary treatment option,” said study investigator Dr Lecia Sequist from the Massachusetts General Hospital, Boston, Massachusetts, US.

The most common adverse events (AEs) experienced by patients in the first cohort were nausea (37 percent), diarrhoea (30 percent), fatigue (28 percent), decreased appetite (28 percent), pyrexia (26 percent), and vomiting (22 percent). Around one-third of the patients had an AE leading to discontinuation of treatment.

The most common all-causality AEs experienced by patients in the second cohort were nausea (52 percent), vomiting (38 percent), diarrhoea (27 percent), fatigue (25 percent), decreased appetite (23 percent), and pyrexia (21 percent). Serious AEs were reported in 29 percent of the patients.

“Overall, the regimen was tolerable, although there was added toxicity with the combination of osimertinib and savolitinib compared with osimertinib given alone. Our understanding of the AE profile of this combination therapy and how to manage these AEs is improving,” Sequist commented.

“Our data suggest that the combination of osimertinib and savolitinib could overcome MET-driven resistance, but certainly further research is needed to determine the final effectiveness of this therapy,” she added.

The ongoing phase II SAVANNAH study (NCT03778229) will further evaluate the combination of osimertinib and savolitinib in these patients with EGFR-mutant, MET-positive NSCLC whose disease has progressed on prior osimertinib. 

Studies have reported that high MET expression is associated with a worse prognosis in patients with NSCLC. The rate of MET amplification in NSCLC has been reported to range from 1 percent to 39 percent. [J Cancer 2018;9:1836-1845] 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 5 days ago
Left ventricular assist devices (LVADs) can reverse pulmonary hypertension secondary to left heart disease regardless of baseline pulmonary vascular resistance, according to a new study.
11 May 2019
Acute kidney injury (AKI) commonly occurs within a year after cancer diagnosis in paediatric patients and is tied to long-term deteriorations in renal function, a recent study has found.
11 May 2019
Women practicing exclusive breastfeeding for 6 months achieve greater postpartum weight loss compared with those exclusively breastfeeding for a shorter duration, according to data from the MILK* study.
Pearl Toh, 13 May 2019
The selective cap-dependent endonuclease inhibitor baloxavir marboxil (hereafter baloxavir) effectively improves influenza symptoms in adolescent patients and those at high risk for influenza complications, according to two subanalyses of the CAPSTONE studies presented at ECCMID 2019.